Insmed’s 2025 Revenue Jumps 67% on Strong BRINSUPRI Launch, Eyes 2026 Milestones in Rare Diseases
BRINSUPRI and ARIKAYCE Drive Insmed’s Record Revenue Growth
Insmed Incorporated capped off 2025 with a 67% surge in total revenues, propelled by a sturdy debut from BRINSUPRI (brensocatib) and international expansion of ARIKAYCE (amikacin liposome inhalation suspension). According to preliminary unaudited results shared at the 44th Annual J.P. Morgan Healthcare Conference, Insmed expects full-year 2025 revenues to reach $606.4 million, up from $363.7 million in 2024.
BRINSUPRI’s First Year: 9,000 Patients and European Approval
BRINSUPRI, approved for non-cystic fibrosis bronchiectasis (NCFB), tallied $172.7 million in its first full year on the U.S. market. By year-end, approximately 4,000 medical professionals had prescribed BRINSUPRI, and a notable 9,000 new patients started therapy in the fourth quarter alone. The drug’s European trajectory brightened with recent approval for NCFB patients age 12 and up with frequent exacerbations, positioning BRINSUPRI for launches in the EU, UK, and Japan during 2026.
ARIKAYCE International Growth and 2026 Guidance
ARIKAYCE exceeded projections with $433.8 million in global sales—a 19% increase from last year—driven by a 41% jump in international revenue. The company now anticipates 2026 worldwide ARIKAYCE revenues between $450 million and $470 million, with major new trial readouts on the horizon.
| Product | Region | 2025 Revenue ($M) | 2024 Revenue ($M) | Growth (%) |
|---|---|---|---|---|
| ARIKAYCE | U.S. | 280.3 | 254.8 | 10 |
| ARIKAYCE | International | 153.5 | 108.9 | 41 |
| ARIKAYCE | Total | 433.8 | 363.7 | 19 |
| BRINSUPRI | U.S. | 172.7 | - | N/A |
| Total Revenues | U.S. | 453.0 | 254.8 | 78 |
| Total Revenues | International | 153.5 | 108.9 | 41 |
| Total Revenues | Total | 606.4 | 363.7 | 67 |
Major Clinical and Commercial Milestones Set for 2026
Insmed has a packed agenda for 2026 with several high-impact trial readouts and launches expected. Notably:
- ARIKAYCE topline data from the Phase 3 ENCORE trial (for broader Mycobacterium avium complex lung disease use) is expected by March or April 2026.
- A new EU launch for BRINSUPRI is planned in the first half of 2026, with launches in the UK and Japan pending regulatory decisions.
- The company expects topline Phase 2b CEDAR study data for BRINSUPRI in hidradenitis suppurativa (HS) in Q2 2026.
- Phase 3 programs for TPIP (treprostinil palmitil inhalation powder) continue in pulmonary conditions, with additional studies planned for PAH, PPF, and IPF later in 2026.
- Expansion into gene therapy candidates and new indications, with preclinical and early clinical programs underway for conditions like Duchenne muscular dystrophy, ALS, and Stargardt disease.
Safety Remains a Focus Amidst Expansion
As Insmed broadens its commercial footprint, it continues to emphasize robust safety monitoring programs. The company flagged key warnings and precautions for both its marketed drugs—BRINSUPRI and ARIKAYCE—relating to dermatological, dental, pulmonary, and auditory adverse events, as well as risk management in special populations such as pediatric and pregnant patients. Ongoing clinical studies and post-market surveillance aim to further characterize benefit-risk profiles as therapies expand into wider geographies and indications.
Looking Ahead: Ambitious Outlook Fueled by Science and Pipeline Depth
Insmed’s momentum is underpinned by a diverse late-stage pipeline, spanning small-molecule, biologic, and genetic therapies across respiratory, immunology, and rare neurologic disorders. With over 30 preclinical programs in development and plans to submit one to two new investigational drug applications (INDs) per year, the company is positioning itself for durable growth.
With BRINSUPRI ramping up, ARIKAYCE setting new highs, and a packed clinical calendar for 2026, Insmed’s strategy is firmly geared toward expanding options for underserved patient populations. Investors and healthcare professionals will want to watch for upcoming data releases and regulatory milestones that could chart the company’s next chapter in both revenue and medical innovation.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI